Compare LITB & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LITB | XBIT |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.1M | 69.8M |
| IPO Year | 2013 | 2015 |
| Metric | LITB | XBIT |
|---|---|---|
| Price | $3.36 | $2.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.1K | ★ 35.6K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.50 | N/A |
| Revenue Next Year | $11.59 | N/A |
| P/E Ratio | $10.96 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.15 | $2.09 |
| 52 Week High | $4.17 | $3.61 |
| Indicator | LITB | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 48.10 | 31.27 |
| Support Level | $2.41 | $2.18 |
| Resistance Level | $3.32 | $2.42 |
| Average True Range (ATR) | 0.20 | 0.06 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 45.83 | 4.08 |
LightInTheBox Holding Co Ltd is a e-commerce company, providing a diverse range of affordable lifestyle products directly to consumers. Its brands include Ador, a women's fashion brand targeting women aged 35-55; the second is a golf apparel brand focusing on female golfers aged 35 and above; the third is a women's light party dress brand for the age group of 30 and above. It offers customers products through websites and mobile applications. The company operates and reviews its performance in two segments: Product sales which consisted of online retailing of consumer products and sales to third-party sellers, and Services which consisted of the provision of logistic services to companies and individual customers.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.